Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
AstraZeneca has been making large quantities of its vaccine in Britain, but has said a contract it signed with the British government requires it to fulfil Britain's order before it can send doses manufactured there abroad, including to the EU.
The company agreed on Friday to publication of its advance purchase agreement with the European Commission. The 41-page contract was published https://bit.ly/2MBIaoU, although certain parts were redacted.
The contract says that AstraZeneca must uses its "Best Reasonable Efforts" to manufacture the EU doses, but the parties disagree on what this means.
AstraZeneca's contention is that this is more of a subjective assessment, but a commission official said on Friday it was an objective legal standard.
The official pointed to a sentence in the contract by which AstraZeneca says it is not under any obligation to others that would impede complete fulfilment of the agreement's requirements.
The commission also contends it does have the right to doses made in Britain and refers to a section at the end of the contract listing two British production sites.
"AstraZeneca shall use its Best Reasonable Efforts to manufacture the vaccine at manufacturing sites located within the EU (which for the purpose of this Section 5.4 only shall include the United Kingdom)," the contract says in a section on manufacturing sites.
The contract does not say whether AstraZeneca is obliged to send vaccines produced in Britain to the European Union.
UPDATE 4-AstraZeneca contract includes UK as 'best effort' base for output to EU
30 01 2021 06:07am AEDT
(Adds AstraZeneca CEO comments)
By Philip Blenkinsop and Alistair Smout
BRUSSELS, Jan 29 (Reuters) - The European Commission's contract with AstraZeneca to supply COVID-19 vaccines includes Britain along with the EU as places where the Anglo-Swedish drugmaker should make its best efforts to manufacture vaccines for the EU.
The contract is at the heart of a dispute over access to vaccines, after AstraZeneca announced last week it would fall short of delivering promised vaccines to the EU by March because of production problems in Belgium.
Speaking after European medical regulators approved the vaccine, AstraZeneca Chief Executive Pascal Soriot said manufacturing glitches were inevitable and the company was focused on boosting supplies to the bloc after resolving most of the issues. [nL1N2K41WI]
Seeking to defuse the row, Soriot said there were millions of doses ready to be shipped to EU countries. The company was working to increase capacity from the projected 31 million doses in the first quarter, using drug substance taken from other parts of the world, he added. [nS8N2II076] [nS8N2II077]
AstraZeneca and the EU had signed a deal for up to 400 million doses of the vaccine. Last week, the firm unexpectedly announced cuts of up to 60% in supplies to the bloc, citing production problems at a Belgian factory, triggering a furious response from the bloc.
The EU is now looking into a scheme to monitor and authorise export of vaccines, potentially blocking them if its own supply is not met.
The EU, whose member states are far behind Israel, Britain and the United States in rolling out vaccines, is standing its ground, pressing the Anglo-Swedish drugmaker to deliver the doses as promised in the contract.
AstraZeneca has been making large quantities of its vaccine in Britain, but has said a contract it signed with the British government requires it to fulfil Britain's order before it can send doses manufactured there abroad, including to the EU.
The company agreed on Friday to publication of its advance purchase agreement with the European Commission. The 41-page contract was published https://bit.ly/2MBIaoU, although certain parts were redacted.
The contract says that AstraZeneca must uses its "Best Reasonable Efforts" to manufacture the EU doses, but the parties disagree on what this means.
AstraZeneca's contention is that this is more of a subjective assessment, but a commission official said on Friday it was an objective legal standard.
The official pointed to a sentence in the contract by which AstraZeneca says it is not under any obligation to others that would impede complete fulfilment of the agreement's requirements.
The commission also contends it does have the right to doses made in Britain and refers to a section at the end of the contract listing two British production sites.
"AstraZeneca shall use its Best
The new thread started today with new code for the company LSEG
I have the honour to be first one in the world visit this thread , congratulations to the company and the shareholders for the complete Refinitiv deal ??????????
LSE boss Schwimmer says "blank cheque" listings could boost London after Brexit
29 Jan 2021 21:34
LONDON, Jan 29 (Reuters) – Britain should replicate New
York's success in listing "blank cheque" companies to boost the
City of London's attractiveness as a global financial centre after Brexit, London Stock Exchange Chief Executive David
Schwimmer said on Friday.
"SPACs clearly have taken off in the U.S. markets. There is increasing curiosity and potential interest in seeing more of them here," Schwimmer told Reuters.
"We do think are opportunities in the UK listings regime to make some changes that would make us a more attractive listing regime while maintaining high standards of corporate governance."
(Reporting by Huw Jones
Editing by Rachel Armstrong) ((huw.jones@thomsonreuters.com; +44 207 542 3326; Reuters
Messaging: huw.jones.thomsonreuters.com@reuters.net)
BUZZ – Vir – Lilly partnership for COVID – 19 therapy an avenue for success – Cowen
29 Jan 2021 00:56
* Drug developer Vir Biotechnology's shares up 14.5% at $95.07 premarket
* Drugmaker Eli Lilly and Co said on Wednesday it was testing its COVID-19 antibody therapy in combination with another treatment by VIR and partner GlaxoSmithKline to fight new variants of the coronavirus ...
* Cos to test LLY's bamlanivimab and VIR's VIR-7831 in combination
* Cowen says the collaboration provides another potential avenue of clinical and commercial success for VIR-7831
* Says the combination therapy will be more effective than either as a monotherapy
* Cowen maintains rating of "outperform"; Avg consensus on
VIR is "buy", with median PT of $61.5- Refinitiv IBES
* VIR gained 560.6% in last 12 months
(Reporting by Trisha Roy in Bengaluru) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;)
Germany is desperate for AstraZeneca vaccine and they play dirty trick with AstraZeneca first they put pressure with company to give them all the quantity of the vaccines they want otherwise they they try to find something faulty in the vaccine so they reduce the international demand for AstraZeneca vaccine then it will be easy for AZ to give them whatever they want .
I wonder why EU treat AstraZeneca so hard when the company said it will delay the vaccine but in the same time Pfizer said the same and EU didn’t talk to them or even research the vaccine or investigate any things why they treatment is so different from the government and the media ? Even UK Media .
London stock market facing blockbuster IPO year
https://economictimes.indiatimes.com/markets/stocks/news/london-stock-market-facing-blockbuster-ipo-year/articleshow/80430639.cms
Trade Alert: The Senior Independent Non-Executive Director Of GlaxoSmithKline plc (LON:GSK), Manvinder Banga, Has Just Spent UK£503k Buying 60% More Shares
https://finance.yahoo.com/news/trade-alert-senior-independent-non-230103685.html
CS doesn’t know the vaccine work and in the report mentioned shingles vaccine - stating it can’t be taken with the Covid vaccine. , in fact this isn’t true and proved CS doesn’t the difference between the Covid 19 vaccine and others Vaccine .
Fact check: COVID-19 and influenza vaccines too different to be directly compared
https://www.reuters.com/article/uk-factcheck-covid-influenza-vaccines/fact-check-covid-19-and-influenza-vaccines-too-different-to-be-directly-compared-idUSKBN28I2UE
Lincolnite - this is copy and paste for the report
HAMBURG (dpa-AFX Analyzer) - The private bank Berenberg has raised the price target for the share of the London Stock Exchange from 9510 to 11800 pence and left the rating at "Buy". The stock exchange operator's paper has what it takes to increase total returns by around 85 percent in the next three years, analyst Chris Turner wrote in a study published on Thursday. Operational improvements should contribute to this, as should share buybacks. / Edh / ag
2021 : You should have these stocks in your portfolio ...
Publication of the original study: 01/13/2021 / 17:07 / GMT
First dissemination of the original study: date not given in study / time not given in study / time zone not given in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) WpHG, Art. 20 VO (EU) 596/2014 for the aforementioned analyst company can be found at http://web.dpa-afx.de/offenlegungspflicht/ Offenlegungs_pflicht.html.
PS: London Stock Exchange Group is a Champions share from the boerse.de share letter. You can download the current share issue here for free ...
Lincolnite - https://www.boerse.de/nachrichten/BERENBERG-London-Stock-Exchange-Group-buy/31503046
LSE : BERENBERG RAISES TARGET PRICE TO 11,800P FROM 9,510P
What is going on with AstraZeneca share price? It should go up today at least 5% but bad luck for poor shareholders in AstraZeneca ,share price is going down no, is this Stockmarket manipulation?
Or something wrong with UK investors doesn’t like to spend money till someone takeovers uK assets At bottom price.